Durchführung einiger Studien in der Anwendung von Tesetaxel bei Brust- und Magenkrebs. Quelle: http://www.genta.com/Press_Releases/2012/...anced_Gastric_Cancer.html
Source: Genta Incorporated Date: January 19, 2012 08:05 ET New Clinical Trial Confirms the Activity of Tesetaxel in Patients With Advanced Gastric Cancer New Results Confirm Response Rate and Low Incidence of Serious Side Effects BERKELEY HEIGHTS, N.J., Jan. 19, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA.OB) today announced results from the Company's Phase 2b, confirmatory clinical trial of tesetaxel in patients with advanced gastric cancer. The trial is lead by investigators from M.D. Anderson Cancer Center, Houston, TX, in collaboration with Northwestern University, Chicago, IL, University of Pennsylvania, Philadelphia, PA, and the Severance Hospital, Seoul, Korea. The data are being presented this week at the GI Cancer Symposium in San Francisco, CA, sponsored by the American Society of Clinical Oncology (ASCO). The study has enrolled 41 patients who progressed on at least one prior chemotherapy regimen that included a platinum compound (cisplatin, oxaliplatin, or carboplatin) and a fluoropyrimidine compound (5-fluorouracil [5-FU] or capecitabine [Xeloda®; Hoffman-La Roche, Inc.]). Two patient cohorts were treated over a range of "flat" (as opposed to "weight-based") doses starting at 40-45 mg (Cohort 1) and 50-60 mg (Cohort 2), whereas Cohort 3 used weight-based dosing at the maximally tolerable dose (MTD) of 27 mg/m2. Doses were repeated every 3 weeks, and overall response rate (ORR) was the trial's primary endpoint. |